AUS
NZ
UK
CA
USA
IND
Highlights
- Imugene (ASX:IMU) appoints experienced finance leader Darren Keamy as CFO and company secretary.
- Keamy brings nearly two decades of expertise from Clinuvel Pharmaceuticals (ASX:CUV).
- His strategic financial leadership contributed to Clinuvel’s market cap growth from A$60 million to over A$2.1 billion.
Imugene (ASX:IMU) has strengthened its leadership team with the appointment of Darren Keamy as its new chief financial officer (CFO) and company secretary. Keamy brings a wealth of experience, having spent 19 years at Clinuvel Pharmaceuticals (ASX:CUV) in the same roles, where he played a pivotal part in the company’s transformation into a globally recognized biotech enterprise.
During his tenure at Clinuvel, Keamy was instrumental in securing more than A$95 million in funding, significantly driving the company’s market capitalisation from approximately A$60 million to a peak of over A$2.1 billion. His expertise spans corporate governance, risk management, financial strategy, and international expansion, making him a strategic addition to Imugene’s executive team.
With extensive experience across global jurisdictions—including the United States, Switzerland, Singapore, Ireland, Monaco, and the United Kingdom—Keamy has built legal and operational frameworks that have enhanced corporate efficiency and regulatory compliance. His deep understanding of investor relations and capital markets further strengthens Imugene’s financial strategy as the company continues to advance its immuno-oncology pipeline.
Prior to his long-standing role at Clinuvel, Keamy held key financial positions at Amcor Limited (ASX:AMC), Salomon Smith Barney (now part of Citigroup), and Superdrug Stores Plc in the UK. His expertise in financial management, risk mitigation, and compliance positions him well to support Imugene’s strategic objectives.
Leslie Chong, managing director and CEO of Imugene, expressed enthusiasm about Keamy’s appointment, stating, “Darren’s outstanding experience in financial management, capital markets, and corporate governance within the life sciences sector makes him a valuable addition to Imugene. His proven ability to drive financial performance and strategic growth will support the company as we continue advancing our immuno-oncology pipeline. We are delighted to have him on board.”
Keamy’s appointment aligns with Imugene’s broader vision of strengthening its leadership team as the company progresses in the immuno-oncology space. With a track record of driving financial success and global expansion, his expertise is expected to be a significant asset in the company’s growth trajectory.
